Avenzoar Pharmaceuticals is a start-up pharmaceutical company based in Encinitas, CA, founded in 2016. They specialize in developing cancer drugs that target and inhibit mechanisms of metastasis and drug resistance, with a focus on pancreatic and liver cancer. Avenzoar currently has three drugs in their pipeline, with their lead drug, AP-001 (aka Metavert), expected to be tested in pancreatic cancer patients in 2024-2025.
Under the leadership of their management team, including CEO Terrance Bruggeman, Avenzoar Pharmaceuticals is committed to fighting cancer by developing small molecule therapeutics that simultaneously target multiple cancer-promoting pathways. They have also assembled a world-class team of consultants and an advisory board to ensure the success of their drug development strategy. With their expertise and dedication, Avenzoar Pharmaceuticals aims to make significant advancements in the treatment of recalcitrant cancers.
Generated from the website